Dementia and Neurocognitive Disorders (대한치매학회지)

Korean Dementia Association (대한치매학회)
권호 표지
DOI QR코드

DOI QR Code

Plasma Oligomeric Beta Amyloid in Alzheimer's Disease with History of Agent Orange Exposure

  • Yang, YoungSoon (Department of Neurology, Veterans Health Service Medical Center) ;
  • Van Giau, Vo (Department of Bionano Technology, Gachon University) ;
  • An, Seong Soo A. (Department of Bionano Technology, Gachon University) ;
  • Kim, SangYun (Department of Neurology, Seoul National University College of Medicine & Neurocognitive Behavior Center, Seoul National University Bundang Hospital)
  • Received : 2016.12.29
  • Accepted : 2017.01.20
  • Published : 2018.06.30
⟨ Previous Next ⟩

Abstract

Background and Purpose: During the Vietnam War, many Korean soldiers were exposed to Agent Orange. Until now, there existed only limited evidence of association between exposure to Agent Orange and Alzheimer's disease (AD). The main pathological feature of AD is brain amyloidosis. To explore the pathophysiological characteristic of AD with Agent Orange exposure, we compared newly developed amyloid beta ($A{\beta}$) oligomer levels in plasma between AD with Agent Orange exposure and without exposure. Methods: We recruited 48 AD patients with Agent Orange exposure and 66 AD patients without Agent Orange. Using the Multimer Detection System technique, which was based on an enzyme-linked immunosorbent assay, we measured $A{\beta}$ oligomers in the plasma of study subjects. Results: Compared to normal control patients, plasma $A{\beta}$ oligomer levels were higher in AD patients regardless of history of Agent Orange exposure. However, AD patients with Agent Orange exposure showed higher plasma $A{\beta}$ oligomer levels than AD patients without Agent Orange. Discussion: This study showed higher plasma $A{\beta}$ oligomer levels in AD patients with Agent Orange exposure compared to AD patients without Agent Orange. This finding suggests the possibility of a different pathophysiology of AD patients with Agent Orange exposure from AD patients without Agent Orange.

Keywords

Acknowledgement

Supported by : VHS Medical Center

References

  1. Yi SW, Hong JS, Ohrr H, Yi JJ. Agent Orange exposure and disease prevalence in Korean Vietnam veterans: the Korean veterans health study. Environ Res 2014;133:56-65. https://doi.org/10.1016/j.envres.2014.04.027
  2. Yang Y, Cheon M, Kwak YT. Is Parkinson's disease with history of Agent Orange exposure different from idiopathic Parkinson's Disease? Dement Neurocognitive Disord 2016;15:75-81. https://doi.org/10.12779/dnd.2016.15.3.75
  3. Zober A, Ott MG, Messerer P. Morbidity follow up study of BASF employees exposed to 2,3,7, 8-tetrachlorodibenzo-p-dioxin (TCDD) after a 1953 chemical reactor incident. Occup Environ Med 1994;51:479-486. https://doi.org/10.1136/oem.51.7.479
  4. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:263-269. https://doi.org/10.1016/j.jalz.2011.03.005
  5. Gong Y, Chang L, Viola KL, Lacor PN, Lambert MP, Finch CE, et al. Alzheimer's disease-affected brain: presence of oligomeric A ${\beta}$ ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci U S A 2003;100:10417-10422. https://doi.org/10.1073/pnas.1834302100
  6. Lesne SE, Sherman MA, Grant M, Kuskowski M, Schneider JA, Bennett DA, et al. Brain amyloid-${\beta}$ oligomers in ageing and Alzheimer's disease. Brain 2013;136:1383-1398. https://doi.org/10.1093/brain/awt062
  7. Larson ME, Lesne SE. Soluble $A{\beta}$ oligomer production and toxicity. J Neurochem 2012;120 Suppl 1:125-139.
  8. Sakono M, Zako T. Amyloid oligomers: formation and toxicity of Abeta oligomers. FEBS J 2010;277:1348-1358. https://doi.org/10.1111/j.1742-4658.2010.07568.x
  9. Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 1991;30:572-580. https://doi.org/10.1002/ana.410300410
  10. Apostolova LG, Hwang KS, Avila D, Elashoff D, Kohannim O, Teng E, et al. Brain amyloidosis ascertainment from cognitive, imaging, and peripheral blood protein measures. Neurology 2015;84:729-737. https://doi.org/10.1212/WNL.0000000000001231
  11. Snyder HM, Carrillo MC, Grodstein F, Henriksen K, Jeromin A, Lovestone S, et al. Developing novel blood-based biomarkers for Alzheimer's disease. Alzheimers Dement 2014;10:109-114. https://doi.org/10.1016/j.jalz.2013.10.007
  12. Doecke JD, Laws SM, Faux NG, Wilson W, Burnham SC, Lam CP, et al. Blood-based protein biomarkers for diagnosis of Alzheimer disease. Arch Neurol 2012;69:1318-1325. https://doi.org/10.1001/archneurol.2012.1282
  13. An SS, Lim KT, Oh HJ, Lee BS, Zukic E, Ju YR, et al. Differentiating blood samples from scrapie infected and non-infected hamsters by detecting disease-associated prion proteins using Multimer Detection System. Biochem Biophys Res Commun 2010;392:505-509. https://doi.org/10.1016/j.bbrc.2010.01.053
  14. Lim K, Kim SY, Lee B, Segarra C, Kang S, Ju Y, et al. Magnetic microparticle-based multimer detection system for the detection of prion oligomers in sheep. Int J Nanomedicine 2015;10:241-250. https://doi.org/10.2217/nnm.14.101
  15. Decoufle P, Holmgreen P, Boyle CA, Stroup NE. Self-reported health status of Vietnam veterans in relation to perceived exposure to herbicides and combat. Am J Epidemiol 1992;135:312-323. https://doi.org/10.1093/oxfordjournals.aje.a116285
  16. Gauthier E, Fortier I, Courchesne F, Pepin P, Mortimer J, Gauvreau D. Environmental pesticide exposure as a risk factor for Alzheimer's disease: a case-control study. Environ Res 2001;86:37-45. https://doi.org/10.1006/enrs.2001.4254
  17. Baldi I, Lebailly P, Mohammed-Brahim B, Letenneur L, Dartigues JF, Brochard P. Neurodegenerative diseases and exposure to pesticides in the elderly. Am J Epidemiol 2003;157:409-414. https://doi.org/10.1093/aje/kwf216
  18. Konjuh C, Garcia G, Lopez L, de Duffard AM, Brusco A, Duffard R. Neonatal hypomyelination by the herbicide 2,4-dichlorophenoxyacetic acid. Chemical and ultrastructural studies in rats. Toxicol Sci 2008;104:332-340. https://doi.org/10.1093/toxsci/kfn085
  19. Urban P, Pelclova D, Lukas E, Kupka K, Preiss J, Fenclova Z, et al. Neurological and neurophysiological examinations on workers with chronic poisoning by 2,3,7,8-TCDD: follow-up 35 years after exposure. Eur J Neurol 2007;14:213-218. https://doi.org/10.1111/j.1468-1331.2006.01618.x
  20. Peper M, Klett M, Frentzel-Beyme R, Heller WD. Neuropsychological effects of chronic exposure to environmental dioxins and furans. Environ Res 1993;60:124-135. https://doi.org/10.1006/enrs.1993.1021
  21. Byers JP, Masters K, Sarver JG, Hassoun EA. Association between the levels of biogenic amines and superoxide anion production in brain regions of rats after subchronic exposure to TCDD. Toxicology 2006;228:291-298. https://doi.org/10.1016/j.tox.2006.09.009
  22. Wan C, Liu J, Nie X, Zhao J, Zhou S, Duan Z, et al. 2, 3, 7, 8-Tetrachlorodibenzo-P-dioxin (TCDD) induces premature senescence in human and rodent neuronal cells via ROS-dependent mechanisms. PLoS One 2014;9: e89811. https://doi.org/10.1371/journal.pone.0089811
  23. Veloso AJ, Chow AM, Ganesh HV, Li N, Dhar D, Wu DC, et al. Electrochemical immunosensors for effective evaluation of amyloid-beta modulators on oligomeric and fibrillar aggregation processes. Anal Chem 2014;86:4901-4909. https://doi.org/10.1021/ac500424t
  24. Lambert MP, Velasco PT, Chang L, Viola KL, Fernandez S, Lacor PN, et al. Monoclonal antibodies that target pathological assemblies of Abeta. J Neurochem 2007;100:23-35. https://doi.org/10.1111/j.1471-4159.2006.04157.x
  25. Shanthi KB, Krishnan S, Rani P. A systematic review and meta-analysis of plasma amyloid 1-42 and tau as biomarkers for Alzheimer's disease. SAGE Open Med 2015;3:2050312115598250.
  26. Kim SY, An SS, Youn YC, Kang SM, Lim KT, Yang YS, et al. Measurement of $A{\beta}$ oligomer in plasma and a significant correspondence to diagnosis of CSF biomarkers and PIB-PET. Poster presented at the Alzheimer's Association International Conference;2015 July 18-23; Washington, D.C. Cambridge, MA: Alzforum; 2015.

Cited by

  1. Potential Fluid Biomarkers for the Diagnosis of Mild Cognitive Impairment vol.20, pp.17, 2018, https://doi.org/10.3390/ijms20174149
  2. APP, PSEN1, and PSEN2 Mutations in Asian Patients with Early-Onset Alzheimer Disease vol.20, pp.19, 2018, https://doi.org/10.3390/ijms20194757
  3. Fascaplysin Derivatives Are Potent Multitarget Agents against Alzheimer’s Disease: in Vitro and in Vivo Evidence vol.10, pp.11, 2018, https://doi.org/10.1021/acschemneuro.9b00503
  4. Association between increased levels of amyloid-β oligomers in plasma and episodic memory loss in Alzheimer’s disease vol.11, pp.1, 2019, https://doi.org/10.1186/s13195-019-0535-7